For menopause specialists around the world, 2002 was a watershed. Before this they were confident about prescribing hormone therapy for the relief of climacteric symptoms for women in their late 40s and 50s. A number of practitioners were looking to the possible long-term benefits of hormone replacement therapy (HRT) and prescribing it to women in their 60s and beyond. This set the scene for large trials to be set up in the 1990s, looking at the long-term risks and benefits of hormone treatments. The Women's Health Initiative (WHI) reported for the combined estrogen and progestogen arm in 2002 1 and the estrogen-only arm in 2004. 2 The Million Women Study (MWS) reported in 2003. 3 Almost overnight, HRT went from being considered a safe, useful cure for climacteric symptoms to being regarded a risky treatment, to be used only in the most severe cases.
When the initial WHI study (combined estrogen/ progestogen vs placebo) reported, 1 the popular press picked up on the fact that the study had been stopped prematurely owing to the increased risk of breast cancer. However, for interested doctors this was not surprising, given the previously published evidence. 4 They were more concerned about the increased risk of coronary heart disease reported in the study. While the second WHI study (estrogen only) 2 and recent reanalysis by age and time since menopause 5 have reassured the medical profession about the likely absence of risk of coronary heart disease among women close to the menopause, patients still worry about the risks of cancer, particularly breast cancer.
The MWS suggested the risks of breast cancer and hormone therapy were even greater than the WHI had indicated. 3 All HRT regimens (estrogen only, combined sequential and continuous combined) were associated with an increased risk. While the overall risks and benefits are not much different to those perceived before 2002, the studies have still had a large effect on the way we treat symptoms now. Confidence in prescribing has been destabilized by the mixed messages.
Publications from the WHI 5 and the MWS 6 in 2007 have provided more analysis of risks and benefits.
A subgroup analysis for the WHI suggested a nonsignificant reduction in the risk of coronary heart disease in women aged 50-59 years in the estrogen-only trial; in the combined trial this reduction was seen in women who started HRT within 10 years of the menopause, adding to the theory of a 'therapeutic window of opportunity'. The latest from the MWS suggests that prolonged use of HRT increases the risk of ovarian cancer by 20%, 7 a worrying headline. Little wonder the patient is confused: one week she is being told that HRT is safer than we thought and the next that the risk of ovarian cancer is increased. However, the attributable risk is very low, with only four extra cases per 10,000 HRT users over five years. This is less than the risk from obesity, lack of exercise, nulliparity or smoking.
Much of the change in prescribing has been influenced by regulatory and advisory bodies. Regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK have provided advice for prescribing doctors. 8 The latest advice confirms that 'For the majority of women who typically use HRT for the short-term treatment of symptoms of the menopause, the benefits of treatment are considered to outweigh the risks'. Specialist menopause societies around the world, such as the International Menopause Society (IMS), the European Menopause and Andropause Society (EMAS), the North American Menopause Society (NAMS) and the British Menopause Society (BMS), have regularly published and updated their advice to prescribers. Many have provided timely advice and press releases for each newly published article to try to put the new evidence into context and avoid the more extreme reporting.
Use of HRT
It has been estimated that, by 1999, 20 million women worldwide were using HRT. 9 A recent study from the UK general practice database shows that prescribing of HRT had fallen by about 50% in 2005. 10 This was a direct consequence of the epidemiological studies and adverse M P Cust Changes in practice from the WHI and MWS publicity. It is too early to tell whether the latest, reassuring data about HRT and cardiovascular disease in younger women will increase the uptake of HRT in the future.
Counselling
One effect of the increased publicity about hormone treatment has been that patients tend to be more informed, but not always better informed, about hormone treatments. As in many areas of medicine, the time taken to counsel a patient has increased. As the risks and benefits become better understood, it is necessary for the doctor to know the patient is making an informed choice. Documentation of discussions becomes ever more important.
With the advent of web-based information, many patients will have done their own background reading before considering HRT. This can be a mixed blessing, as there is plenty of mis-information on the Internet, as well as useful websites. However, with national websites such as www.menopausematters.co.uk experiencing over 50,000 hits per day, 11 patients' desire for knowledge seems insatiable.
Prescribing
The advice from the regulatory authorities is to prescribe HRT at the lowest effective dose for the shortest time needed to control the patient's symptoms. 8 Prescribers tend to try to use lower doses than previously, on the assumption that the risks associated with low-dose hormone treatment will be less. Many patients feel happier on a lower dose and will be prepared to compromise their symptom relief for the knowledge that they are taking a low-dose hormone treatment. The pharmaceutical companies have responded by providing lower-dose preparations.
In order to see whether a patient still needs HRT, many are advised to try without HRT after a few years. When stopped abruptly, patients may get rebound symptoms. In the WHI trial, over 50% of women who stopped HRT abruptly developed moderate or severe symptoms. 12 For patients who have been taking HRT for some time, it seems logical to try to wean them off slowly by gradually reducing the dose.
Regimens of HRT
While the risk of endometrial cancer appears to be least among women taking continuous combined HRT (and higher for those on combined sequential regimens or estrogen only), 13 the risk of breast cancer appears to be greatest for this regimen. 3 It may be tempting to use estrogen-only HRT for women at high risk of breast cancer (and keep a check on the endometrium by biopsy or scan). However, if the woman still has her uterus, the resulting erratic bleeding usually precludes long-term use.
The use of the MIRENA IUS (levonorgestrel-releasing intrauterine system) as the progestogen component of combined HRT is increasing. It is very effective at giving 'bleed free' HRT. The concentration of levonorgestrel is high in the endometrium and very little is absorbed into the systemic circulation. It remains to be seen whether this method of delivering progestogen will result in lower risks of breast cancer.
The WHI trials confirmed an increase in the risk of thrombosis with oral HRT. However, a comparative study of oral and transdermal HRT suggests that when estrogen is given transdermally there is no increased risk of thromboembolism. 14 Thus, for patients at higher risk of thrombosis, it appears logical to use non-oral routes of administration.
Many women took themselves off HRT in 2002 because of their fears about its dangers. For those who stayed off treatment, in the subsequent years some developed atrophic vaginal symptoms, with dyspareunia, urgency and frequency of micturition. The use of topical vaginal estrogen is highly effective for these problems and its prescription has increased.
Alternatives to HRT
With all the adverse publicity, there has been a proliferation in alternative treatments offered for menopausal symptoms. For patients who eventually attend their doctor to seek treatment, over 80% will have tried nonprescribed treatments already. Many of these products do not provide good symptom relief, and they are often no better than placebo. At best they will give 50-60% symptom reduction, compared with 80-90% with traditional HRT. 15 Furthermore, because most alternative therapies do not require a doctor to prescribe them, the patient expectation is that these will be without side-effects. For some preparations this is not the case. There is an absence of safety data regarding the use of isoflavones and phytoestrogens in patients with hormone-dependent breast cancer.
Conclusions
For the most part, the estimates of risks and benefits of HRT are little changed from the 1990s. A recent editorial in the BMJ 16 suggests that 'hormone replacement therapy comes full circle' as the latest evidence from the WHI and MWS are assimilated. However, because of the increased adverse publicity over the last five years, the uptake and prescribing of HRT have changed markedly. The hope is that in the next five years the messages coming out about HRT will be more consistent and allow both patients and prescribers more confidence to know where, when and how to prescribe HRT appropriately.
